Target intelligence / Profile preview

Retinoic acid-inducible gene I (RIG-I)

Target
RIG-I
Molecular classification
Enzyme, Receptor, RNA helicase, Pattern recognition receptor
01

Overview

Retinoic acid-inducible gene I (RIG-I), encoded by the DDX58 gene, is a cytosolic pattern recognition receptor (PRR) and DExD/H-box RNA helicase that plays a critical role in the host innate immune response. It primarily senses short, double-stranded RNA (dsRNA) and single-stranded RNA containing a 5'-triphosphate or 5'-diphosphate moiety, which are characteristic of viral replication intermediates but absent in healthy host cells. Upon ligand binding, RIG-I undergoes a conformational change that exposes its N-terminal caspase activation and recruitment domains (CARDs), enabling homooligomerization and interaction with the mitochondrial antiviral-signaling protein (MAVS). This interaction initiates a signaling cascade that activates transcription factors IRF3, IRF7, and NF-κB, driving the production of type I and type III interferons and pro-inflammatory cytokines.

In addition to its role in antiviral defense, RIG-I activation triggers immunogenic cell death preferentially in cancer cells and remodels the tumor microenvironment, making it a highly attractive target for cancer immunotherapy. Conversely, aberrant or constitutive activation of RIG-I due to gain-of-function mutations is associated with autoimmune and autoinflammatory disorders, such as Singleton-Merten syndrome and lupus nephritis, where RIG-I inhibitors or downstream JAK inhibitors are being explored as therapeutic strategies.

Other names
DDX58RIG-IRIG1DEAD box protein 58ATP-dependent RNA helicase DDX58Retinoic acid-inducible gene 1 proteinRIG-I-like receptor 1RLR-1SGMRT2
02

Mechanism of action

RIG-I agonists mimic viral double-stranded RNA (dsRNA) with 5'-triphosphate ends, binding to the helicase and C-terminal domains of RIG-I. This induces a conformational change that exposes the N-terminal caspase activation and recruitment domains (CARDs), allowing interaction with mitochondrial antiviral-signaling protein (MAVS). This triggers downstream signaling via TBK1 and IKKε, activating IRF3, IRF7, and NF-κB, which leads to the production of type I/III interferons and pro-inflammatory cytokines, as well as immunogenic cell death in cancer cells. RIG-I inhibitors block the ATPase activity or RNA-binding of RIG-I to suppress aberrant interferon signaling.

03

Biological functions

Immune responseInnate immunitySignal transductionApoptosisAntiviral defenseType I interferon production
04

Disease associations

InfectionCancerInflammationAutoimmune diseaseSingleton-Merten syndromeLupus nephritisAicardi-Goutieres syndrome
05

Safety considerations

Systemic inflammatory response syndrome (SIRS) or cytokine storm due to excessive interferon and cytokine releaseAutoimmune flare-ups or interferonopathies (e.g., lupus-like symptoms, Singleton-Merten syndrome-like pathology)Pancreatitis (as seen with inarigivir)Toxicity associated with delivery vehicles (e.g., polyethylenimine/PEI-induced membrane destabilization and cytotoxicity)Off-target activation of other pattern recognition receptors (PRRs)
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Type I interferon signatureInterferon-stimulated genes (ISGs)RIG-I expression levelPD-L1 expressionCXCL10IL-6TNF-alpha

Beyond the preview

Go deeper on Retinoic acid-inducible gene I (RIG-I).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retinoic acid-inducible gene I (RIG-I).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call